{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:48:47Z","timestamp":1760784527736},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/jjco\/hyy114","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T12:36:59Z","timestamp":1531917419000},"page":"950-952","source":"Crossref","is-referenced-by-count":8,"title":["Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy"],"prefix":"10.1093","volume":"48","author":[{"given":"Hironobu","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Yanai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital East"},{"name":"Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital"},{"name":"Japan Supportive, Palliative and Psychosocial Oncology Group: J-SUPPORT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Uchitomi","sequence":"additional","affiliation":[{"name":"Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital"},{"name":"Japan Supportive, Palliative and Psychosocial Oncology Group: J-SUPPORT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Data Management Section, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Mori","sequence":"additional","affiliation":[{"name":"Data Management Section, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"key\n\t\t\t\t20181019005305336_hyy114C1","first-page":"103","article-title":"Proposal for Classifying the Acute Emetogenicity of Cancer Chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C2","author":"Japanease Society of Clinical Oncology clinical practice guidelines for anti-emesis in oncology 2015. Version 2. Kanehara, Tokyo"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C3","first-page":"1601","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy:TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C4","first-page":"87","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C5","first-page":"57","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C6","first-page":"245","article-title":"Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium","volume":"390","author":"Bymaster","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C7","first-page":"134","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C8","first-page":"883","article-title":"NCCN Guidelines Insights: antiemesis, Version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C9","first-page":"3240","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C10","first-page":"675","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonsetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"key\n\t\t\t\t20181019005305336_hyy114C11","first-page":"382","article-title":"A double-blind randomized phase II study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/10\/950\/26001154\/hyy114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:53:10Z","timestamp":1539910390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/10\/950\/5073294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,8,14]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy114","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,8,14]]}}}